KLRC1 and head and neck squamous cell carcinoma: In addition, increasing evidence indicates the frequent formation of dual immune checkpoints (PD-L1/PD1 and HLA-E/NKG2A) in HNSCC (27, 28), accounting for the limited effects of nivolumab.